CITIUS ONCOLOGY, INC. cotiza a 0.81 USD y tiene una capitalización bursátil de $86M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headqu…
| Periodo | 2026-05 | 2026-02 | 2025-12 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.27 | $-0.06 | $-0.06 | $-0.08 |
| Estimado | $-0.01 | $-0.04 | $-0.06 | $-0.15 |
| Sorpresa | -2600.0% | -50.0% | +0.0% | +46.7% |
| Métrica | CTOR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -55.2% | -40.4% | -14.8% |
| ROA | -24.5% | -32.0% | +7.5% |
| Current Ratio | 0.56 | 2.84 | -2.28 |
| Debt / Equity | — | 0.28 | — |